Issues
Let’s start with some remarkable statistics.
Nvidia’s (NVDA) fourth-quarter revenue reported yesterday was $68 billion, up 73% from the same period last year. It now makes more revenue in a single quarter than most chip competitors generate in an entire year. Nvidia’s profit for the last 12 months was $120 billion. Just three years ago, Nvidia’s profit was $4.4 billion.
It is estimated that more than one-third of the value of the stock market is represented by companies based in the San Francisco Bay/Silicon Valley area.
Nvidia’s (NVDA) fourth-quarter revenue reported yesterday was $68 billion, up 73% from the same period last year. It now makes more revenue in a single quarter than most chip competitors generate in an entire year. Nvidia’s profit for the last 12 months was $120 billion. Just three years ago, Nvidia’s profit was $4.4 billion.
It is estimated that more than one-third of the value of the stock market is represented by companies based in the San Francisco Bay/Silicon Valley area.
We continue to get solid signals from the White House that cannabis rescheduling is on track. That’ll be a significant catalyst for cannabis stocks. The only question is the timing. That remains uncertain and probably unknowable. Cannabis stocks remain a buy on weakness ahead of this catalyst.
The background here is that last December, President Donald Trump signed an executive order directing the Justice Department to move cannabis to Schedule III from Schedule I under the Controlled Substances Act.
The background here is that last December, President Donald Trump signed an executive order directing the Justice Department to move cannabis to Schedule III from Schedule I under the Controlled Substances Act.
The bull market has broadened out beyond technology in a big way. While the S&P 500 is about even for the year so far, most market sectors are beating the index, and by a lot. In fact, six of the eleven sectors have a better than 8% YTD return, not even two months into the year.
The new market dynamic is having a profound impact on the portfolio. Several stocks that had been dead weight in the portfolio have soared in recent months to 52-week highs. The new market has turned previously underperforming stocks into strong income generators.
It has been a strong run for several portfolio stocks. But a largely successful earnings season is almost over. That means there will be no obvious catalyst to continue driving stocks higher, at least for now. The situation makes it a better time to capitalize on recent price surges instead of adding more positions and hoping for more.
Under the current circumstances, the biggest market opportunity right now is income. In this issue, I highlight three more high-priced covered calls on stocks that have had strong rallies.
The new market dynamic is having a profound impact on the portfolio. Several stocks that had been dead weight in the portfolio have soared in recent months to 52-week highs. The new market has turned previously underperforming stocks into strong income generators.
It has been a strong run for several portfolio stocks. But a largely successful earnings season is almost over. That means there will be no obvious catalyst to continue driving stocks higher, at least for now. The situation makes it a better time to capitalize on recent price surges instead of adding more positions and hoping for more.
Under the current circumstances, the biggest market opportunity right now is income. In this issue, I highlight three more high-priced covered calls on stocks that have had strong rallies.
In researching potential candidates for this month’s edition of the newsletter, I narrowed down my final list of top choices to the usual 10 stocks. What caught my attention when reviewing the list, however, was how many of them were in the healthcare sector—in particular, the therapeutic arena.
I was gratified by this discovery since I feel that a.) medical stocks are underrepresented in the portfolio, and b.) the sector is at once defensive in nature (always a good thing in my estimation) yet also poised to benefit from ongoing sector rotation.
I was gratified by this discovery since I feel that a.) medical stocks are underrepresented in the portfolio, and b.) the sector is at once defensive in nature (always a good thing in my estimation) yet also poised to benefit from ongoing sector rotation.
Before we dive into this week’s covered call idea, I need to address two items.
First, we are going to sell our RKT stock as the February call that we sold expired worthless, leaving us with our stock position.
First, we are going to sell our RKT stock as the February call that we sold expired worthless, leaving us with our stock position.
It remains about as mixed an environment as we can remember, which does mean the risk of some sort of convulsion (a correction, a re-rotation into laggards, etc.) is elevated. That said, as opposed to the on-again, off-again action from certain areas in January, we have seen the winners persist of late, so that’s where we’re focusing—while also holding some cash and raising stops along the way given what’s going on. For the moment, we’ll stick with a level 6 on the Market Monitor, but again, we’re OK taking swings at strong stocks.
This week’s list is very heavy on the cyclical side of things, with many names perking up and out of long ranges. Our Top Pick has a solid growth profile and has emerged on the upside after a six-month choppy phase.
This week’s list is very heavy on the cyclical side of things, with many names perking up and out of long ranges. Our Top Pick has a solid growth profile and has emerged on the upside after a six-month choppy phase.
Tariffs rejected. Big shortfall in GDP growth. Possible emerging conflict with Iran. There were enough headlines last week – and really, Friday alone! – to make your head spin. And yet … stocks were mostly calm, with no sudden movements in either direction. As always, the stock charts matter more than the headlines, at least when it comes to investing.
So, let’s stay the course, which this week means adding a well-known stock that continues to thrive in the midst of the ongoing travel resurgence. It was Mike Cintolo’s Top Pick in his Cabot Top Ten Trader momentum-trading advisory last week.
Details inside.
So, let’s stay the course, which this week means adding a well-known stock that continues to thrive in the midst of the ongoing travel resurgence. It was Mike Cintolo’s Top Pick in his Cabot Top Ten Trader momentum-trading advisory last week.
Details inside.
Despite early-week angst over continued AI disruption fears, markets steadied into the weekend as tech found fresh legs and headline risk eased after a key Supreme Court ruling altered the U.S. tariff landscape. The rebound in mega-cap names helped sentiment improve off midweek lows, though small caps lagged. For the week, the S&P 500 rallied 1.1%, the Dow advanced 0.3%, and the Nasdaq led with a gain of 1.5%, while the Russell 2000 was essentially flat.
Despite early-week angst over continued AI disruption fears, markets steadied into the weekend as tech found fresh legs and headline risk eased after a key Supreme Court ruling altered the U.S. tariff landscape. The rebound in mega-cap names helped sentiment improve off midweek lows, though small caps lagged. For the week, the S&P 500 rallied 1.1%, the Dow advanced 0.3%, and the Nasdaq led with a gain of 1.5%, while the Russell 2000 was essentially flat.
It’s not 1999 out there, but the Model Portfolio has been doing OK despite the choppy, challenging, crosscurrent-filled market of late, partially thanks to an interesting dynamic—while the top-down evidence really hasn’t changed much in recent weeks (if anything, it’s probably worsened a bit, especially when it comes to growth funds and our Aggression Index), we are definitely seeing more individual stocks perk up, both within AI and in cyclical areas.
We do have two or three moves we’re close to making—while we’re not eager to be heavily invested given the evidence, we have a lot of cash and are likely to put some to work soon. But, tonight, we’ll stand pat and see if opportunities arise in the next few days—while also seeing if the Nasdaq’s test of its recent low holds. Bottom line, stand pat here, but we’ll be in touch with any changes in the days ahead.
We do have two or three moves we’re close to making—while we’re not eager to be heavily invested given the evidence, we have a lot of cash and are likely to put some to work soon. But, tonight, we’ll stand pat and see if opportunities arise in the next few days—while also seeing if the Nasdaq’s test of its recent low holds. Bottom line, stand pat here, but we’ll be in touch with any changes in the days ahead.
With the market’s rotation into energy, industrial and other “unloved” stocks continuing well into 2026, we’re leaning deeper into the trends.
This month’s issue focuses on yet another specialty industrial player, an under-the-radar biofuel story, and an energy name with exposure to strong, international markets.
As always, the goal is to stay aligned with what’s working.
Enjoy!
This month’s issue focuses on yet another specialty industrial player, an under-the-radar biofuel story, and an energy name with exposure to strong, international markets.
As always, the goal is to stay aligned with what’s working.
Enjoy!
Despite a small bounce Friday on softer inflation data that eased some knee-jerk selling, markets finished on their back foot as renewed investor anxiety around artificial-intelligence disruption rippled through tech and cyclical stocks. Growth names lagged, pressure widened beyond software to financials and real estate, and defensive sectors outperformed amid falling Treasury yields that weren’t enough to stem the slide. By week’s end, the S&P 500 had fallen 1.4%, the Dow Jones had lost 1.2%, and the Nasdaq Composite had tumbled 2.1%.
Updates
It has been called by many pundits the biggest speculative event since the late ‘90s Internet stock mania. I’m referring, of course, to the widely referenced “AI bubble” that has been in play for the better part of the last three years.
But is it truly a “bubble” in the historical sense of the term? The answer to this question is salient for us not only as investors, generally speaking, but also as it concerns at least a couple of the stocks in our portfolio—namely Intel (INTC) and Centuri Holdings (CTRI).
But is it truly a “bubble” in the historical sense of the term? The answer to this question is salient for us not only as investors, generally speaking, but also as it concerns at least a couple of the stocks in our portfolio—namely Intel (INTC) and Centuri Holdings (CTRI).
WHAT TO DO NOW: It’s not 2008 out there, but the market environment remains very challenging, especially for growth, where most indexes, funds and stocks are struggling. That said, we have started to see some growth names emerge on the upside, and our watch list is growing—if we can see more than a day or two of strength, we’d like to put some money to work. But until then, we’re content to stay close to shore and patiently wait for growth stocks to get moving. In the Model Portfolio, we’re placing Axsome Therapeutics (AXSM) on Hold tonight; our cash position is still just above 50%.
It’s been an interesting week here in Rhode Island, where most people are finally dug out from the roughly three feet of snow that fell across the state Sunday night and into Monday.
Growing up in Vermont, major snowstorms were certainly disruptive. But more often than not, it was all about how we would get to the ski resort without going off the road.
Growing up in Vermont, major snowstorms were certainly disruptive. But more often than not, it was all about how we would get to the ski resort without going off the road.
Hello from sunny Florida!
I am on vacation with my family this week, taking a much-needed break from the harsh, snowy Vermont winter (and narrowly making it down here ahead of the latest blizzard to dump another foot or two of snow on the Northeast). But with so much going on in the market – tariffs rejected! GDP growth slowing! AI panic! – I wanted to provide an update on everything that’s going on with our stocks.
I am on vacation with my family this week, taking a much-needed break from the harsh, snowy Vermont winter (and narrowly making it down here ahead of the latest blizzard to dump another foot or two of snow on the Northeast). But with so much going on in the market – tariffs rejected! GDP growth slowing! AI panic! – I wanted to provide an update on everything that’s going on with our stocks.
It’s the same basic market story as it has been for the last four months. Technology is floundering while other sectors are killing it. But a couple of events occurring this week could potentially change the dynamic.
For value-focused investors, this year’s prologue has been a welcome change from the turmoil experienced in early 2025.
In just the past few weeks, some of last year’s most ignored or underappreciated laggards have posted outsized gains, with rallies that have made even momentum-driven tech stock traders envious. Even more remarkable is the fact that much of that strength has been concentrated in ultra-defensive areas of the market like consumer staples, utilities and healthcare.
In just the past few weeks, some of last year’s most ignored or underappreciated laggards have posted outsized gains, with rallies that have made even momentum-driven tech stock traders envious. Even more remarkable is the fact that much of that strength has been concentrated in ultra-defensive areas of the market like consumer staples, utilities and healthcare.
The market rotation continues to be the main story out there this week, though rumblings of a potential strike on Iran, an update from the January FOMC meeting, and a slew of earnings reports and economic data releases have been giving investors plenty to think about.
In terms of the rotation, the equal‑weight S&P 500 ETF (RSP) is up 5.5% so far this year, illustrating that leadership is broadening beyond the narrow group of mega‑cap stocks that drove much of last year’s performance.
Year to date, the S&P 600 SmallCap Index is up 8.3% and the S&P 400 Mid‑Cap Index is up 7.9%. Both are comfortably outperforming the S&P 500, which is up just 0.1%, and the Nasdaq, which is down 2.1%.
In terms of the rotation, the equal‑weight S&P 500 ETF (RSP) is up 5.5% so far this year, illustrating that leadership is broadening beyond the narrow group of mega‑cap stocks that drove much of last year’s performance.
Year to date, the S&P 600 SmallCap Index is up 8.3% and the S&P 400 Mid‑Cap Index is up 7.9%. Both are comfortably outperforming the S&P 500, which is up just 0.1%, and the Nasdaq, which is down 2.1%.
Happy Chinese New Year! The year of the horse is upon us.
China is expecting an incredible 9.5 billion trips to be made during the 40-day Lunar New Year travel period. Chinese automakers are also on the move as the country’s numerous brands sold nearly 200,000 vehicles in Britain last year, doubling their market share to almost 10%.
China is expecting an incredible 9.5 billion trips to be made during the 40-day Lunar New Year travel period. Chinese automakers are also on the move as the country’s numerous brands sold nearly 200,000 vehicles in Britain last year, doubling their market share to almost 10%.
As U.S. investors have shifted from risk-on to risk-off mode in recent months, a clear disparity between the “haves” and the “have-nots” has materialized.
Let’s start with the “have-nots.” Financials have fared the worst so far this year (-4.7%), followed by technology (-3.1%), communication services and consumer discretionary (-2.8% each). The downturn in the two tech-related sectors in particular is a stark departure from recent years, when technology led the charge of the current bull market.
Let’s start with the “have-nots.” Financials have fared the worst so far this year (-4.7%), followed by technology (-3.1%), communication services and consumer discretionary (-2.8% each). The downturn in the two tech-related sectors in particular is a stark departure from recent years, when technology led the charge of the current bull market.
Cyclical stocks are soaring and technology is floundering in the transformed market.
The bull market is turned upside down. For most of the first three years, technology, and particularly AI stocks, soared while most other stocks did very little. Now, previously meandering stocks are killing it while technology sinks.
The bull market is turned upside down. For most of the first three years, technology, and particularly AI stocks, soared while most other stocks did very little. Now, previously meandering stocks are killing it while technology sinks.
Strong fourth-quarter earnings are confirming what the market was already doing.
Current estimates based on earnings reported so far are for 13.2% overall S&P earnings growth for the quarter. It’s a solid quarter and the fifth straight quarter of double-digit earnings growth. In terms of sector performance, cyclical companies are killing it, and technology is floundering, just like before earnings.
Current estimates based on earnings reported so far are for 13.2% overall S&P earnings growth for the quarter. It’s a solid quarter and the fifth straight quarter of double-digit earnings growth. In terms of sector performance, cyclical companies are killing it, and technology is floundering, just like before earnings.
Like many coffee aficionados, I have something of a love/hate relationship with Starbucks (SBUX). My main gripe is that the company’s food and beverage offerings have always been pricey compared to the fare served in most fast-food restaurants and run-of-the-mill coffee houses.
Alerts
Today’s 2014 Top Picks update is a Chinese direct-selling company whose management recently increased its second-quarter revenue projections to $86 million to $88 million, from its previous forecast of no more than $86 million.
Light in the Box (LITB)
from Cabot China & Emerging Markets Report
There’s no denying that Light in the...
Light in the Box (LITB)
from Cabot China & Emerging Markets Report
There’s no denying that Light in the...
Today’s 2014 Top Picks update is receiving new Wall Street attention, with upgrades to “accumulate” and “outperform” at Ardour Corp. and Boenning & Scattergood, respectively.
Calgon Carbon (CCC)
from The Periscope Report
Our top stock for 2014 is Calgon Carbon (CCC), which is up 11% this year. CCC is a leader in “carbon...
Calgon Carbon (CCC)
from The Periscope Report
Our top stock for 2014 is Calgon Carbon (CCC), which is up 11% this year. CCC is a leader in “carbon...
Today’s 2014 Top Picks update is a voice and language solutions provider that is rumored to be the target of a buyout.
Nuance (NUAN)
from The National Investor
Nuance (NUAN) has been a timely and solid addition, rising about 40% following our entry back in December. The company has showed some early success...
Nuance (NUAN)
from The National Investor
Nuance (NUAN) has been a timely and solid addition, rising about 40% following our entry back in December. The company has showed some early success...
Today’s 2014 Top Picks update is a low-priced stock that has seen its turnaround slow, but has lots of cash and no debt.
Agjunction (AJX.TO)
from Contra the Heard
Agjunction (AJX.TO) has run into some tough sledding. As CEO/President Rick Heiniger stated, “General weakness within the agriculture markets in the first quarter of...
Agjunction (AJX.TO)
from Contra the Heard
Agjunction (AJX.TO) has run into some tough sledding. As CEO/President Rick Heiniger stated, “General weakness within the agriculture markets in the first quarter of...
This networking company debuted its IPO in March, and it is disrupting processor speed, industry-wide.
A10 Networks (ATEN)
from New Technology Superstars
A10 Networks (ATEN) creates network appliances and software that manage the load on web and network servers to minimize lag and maximize reliability. In other words, if you think of the...
A10 Networks (ATEN)
from New Technology Superstars
A10 Networks (ATEN) creates network appliances and software that manage the load on web and network servers to minimize lag and maximize reliability. In other words, if you think of the...
Auxilio (AUXO)
from The Quiet Investor
I still like Auxilio (AUXO), though it is up only a dime or so since the beginning of the year.
The first quarter was a bit disappointing, with earnings negligible and down from the $0.04 of the final quarter of 2013. Mostly they were one-off expenses, plus...
from The Quiet Investor
I still like Auxilio (AUXO), though it is up only a dime or so since the beginning of the year.
The first quarter was a bit disappointing, with earnings negligible and down from the $0.04 of the final quarter of 2013. Mostly they were one-off expenses, plus...
One contributor says “sell” and the other recommends a “buy” on this oil and gas industry servicing company.
Sell: Core Laboratories NV (CLB)
from Louis Navellier’s Blue Chip Growth Updated from Investment Digest 751, November 20, 2013
I recently provided an update on Core Labs (CLB) and how the stock hasn’t lived up...
Sell: Core Laboratories NV (CLB)
from Louis Navellier’s Blue Chip Growth Updated from Investment Digest 751, November 20, 2013
I recently provided an update on Core Labs (CLB) and how the stock hasn’t lived up...
A differing opinion:
Buy: Core Laboratories NV (CLB)
from The Complete Investor
Before Warren Buffett, the word “franchise” referred to sports teams or perhaps to utilities that controlled a particular market by virtue of legal rights or regulatory authority. Buffett’s genius was to extend the concept to companies that controlled markets because of...
Buy: Core Laboratories NV (CLB)
from The Complete Investor
Before Warren Buffett, the word “franchise” referred to sports teams or perhaps to utilities that controlled a particular market by virtue of legal rights or regulatory authority. Buffett’s genius was to extend the concept to companies that controlled markets because of...
This biotech has been posting double-digit sales and triple-digit earnings growth. The company beat first quarter estimates, earning $0.97 vs. the $0.25 analysts had expected.
Anika Therapeutics, Inc. (ANIK)
from Validea Hot List
Small-Cap Growth Investor
Based on: Motley Fool
Guru Score: 93%
Anika Therapeutics, Inc. (ANIK) develops, manufactures and commercializes therapeutic products for tissue protection,...
Anika Therapeutics, Inc. (ANIK)
from Validea Hot List
Small-Cap Growth Investor
Based on: Motley Fool
Guru Score: 93%
Anika Therapeutics, Inc. (ANIK) develops, manufactures and commercializes therapeutic products for tissue protection,...
Today’s 2014 Top Picks update is an energy company. It recently reported first quarter revenues of NIS 9 billion and net income, excluding amortization due to assets in the process of being sold, of approximately NIS 111 million (Israeli currency).
Delek Group (DGRLY)
from Global Investing
Delek Group (DGRLY) was long-considered the Berkshire...
Delek Group (DGRLY)
from Global Investing
Delek Group (DGRLY) was long-considered the Berkshire...
This auto supplier has a more than 30% market share in a rapidly-expanding market.
Sensata Technologies (ST)
from Top Stock Insights
Sensata (ST) is one of the world’s leading designers of sensors and controls for automotive, residential, commercial and industrial markets.
The company’s recovery out of the 2008-2009 recession was swift—revenues popped 36% in...
Sensata Technologies (ST)
from Top Stock Insights
Sensata (ST) is one of the world’s leading designers of sensors and controls for automotive, residential, commercial and industrial markets.
The company’s recovery out of the 2008-2009 recession was swift—revenues popped 36% in...
This company’s Weibo business had 22 million visitors the first day of the World Cup, and the company has more than $1 billion in cash on its balance sheet.
Sina Corporation (SINA)
from The Value Bounce
Sina Corporation (SINA) is one of China’s top Internet companies, offering advertising driven portals for both desktop...
Sina Corporation (SINA)
from The Value Bounce
Sina Corporation (SINA) is one of China’s top Internet companies, offering advertising driven portals for both desktop...
Portfolios
Strategy
Our Cabot Top Ten Trader’s market timing system consists of two parts—one based on the action of three select, growth-oriented market indexes, and the other based on the action of the fast-moving stocks Cabot Top Ten features.